- VC firm Vivo Capital outlays $740m for biotech investment Pharmaceutical Technology
- Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs Fierce Biotech
- Vivo Capital Closes Opportunity Fund FIN News
- Vivo Capital closes on $740m for third cycle of evergreen public fund Venture Capital Journal
- Healthcare specialist Vivo Capital closes third Opportunity Fund cycle at $740m Alternatives Watch
Recent Comments